Central Government New Programme To Promote Research In Pharma Centeral Government

New Delhi: Finance Minister Nirmala Sitharaman announced launch of a new programme to promote research in pharmaceuticals with a view to promoting growth of the sector. She also said facilities in select ICMR (Indian Council of Medical Research) labs will be made available for research by public and private medical faculties.

The domestic pharma industry had demanded that Budget 2023-24 should help fuel innovation and R&D, which will set the pace for propelling the pharmaceutical industry. The Organization of Pharmaceutical Producers of India had demanded that the government encourage the transition to a discovery-oriented and science-driven approach by offering fiscal incentives and supportive policies in order for the life sciences sector to truly contribute to the vision of Aatmanirbhar Bharat.

Charu Sehgal, Partner, Deloitte India said,” The announcement of providing investment and setting up centres of excellence to promote research and development in pharma is much needed and will help India move up the value chain in the life sciences sector.   The focus on providing skilled manpower availability for high-end research and manufacturing in the medical technology sector will help India become more self reliant and reduce the current high dependence on imports, Sehgal added.

  • Related Posts

    • Pharma
    • January 2, 2025
    • 20 views
    Kwality Pharma gains on securing RCGM approval for Erythropoietin

    Kwality Pharmaceuticals rose 3.19% to Rs 895 after the company secured approval from the Review Committee on Genetic Manipulation (RCGM) to begin pre-clinical toxicity studies for the recombinant Erythropoietin product,…

    • Pharma
    • January 2, 2025
    • 195 views
    Sun Pharma sells entire stake in Japanese arm to Zaza Industrial Holdings

    Sun Pharmaceutical Industries has announced the 100 per cent sale of its step-down subsidiary, Sun Pharma Japan Technical Operations, to Zaza Industrial Holdings K.K., Japan. The decision marks a strategic…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Kwality Pharma gains on securing RCGM approval for Erythropoietin

    Kwality Pharma gains on securing RCGM approval for Erythropoietin

    Man held with drugs worth Rs 2.50 cr, planned for New Year supply in Bengaluru

    Man held with drugs worth Rs 2.50 cr, planned for New Year supply in Bengaluru

    Sun Pharma sells entire stake in Japanese arm to Zaza Industrial Holdings

    Sun Pharma sells entire stake in Japanese arm to Zaza Industrial Holdings

    Bliss GVS Pharma Reaches 52-Week High of Rs. 181.35 with 42.53% Annual Return

    Bliss GVS Pharma Reaches 52-Week High of Rs. 181.35 with 42.53% Annual Return

    New Pharma Rules In India Effective Today: Are MSMEs Ready? What Will Change For The Industry

    New Pharma Rules In India Effective Today: Are MSMEs Ready? What Will Change For The Industry

    Sun Pharma To Sell 100 Percent Stake In Japanese Arm

    Sun Pharma To Sell 100 Percent Stake In Japanese Arm